spacer
home > ebr > spring 2017 > opening doors
PUBLICATIONS
European Biopharmaceutical Review

Opening Doors

The world is currently engaged in an unprecedented, transformational effort to achieve a set of 17 ‘broad and universal’ policy goals that seek to bring greater prosperity, security and dignity to all by 2030 (1). The Sustainable Development Goals are ambitious and highlight some important issues like poverty reduction, universal health and education as well as social justice for all. A key driver of this change that applies to all goals – including the one on health – is Goal 17, to revitalise global partnerships that “mobilise and share knowledge, expertise, technology and financial resources” (2).

New Ways of Working

In the field of global health, the elimination of neglected and infectious diseases such as malaria, tuberculosis (TB), AIDS and the Zika virus is a keen focus of interest. Scientists in both public and private sectors around the world are coming together through product development partnerships to share the very resources outlined by Goal 17 in order to develop new medicines for these debilitating and fatal diseases.

Recently, there has been a growing appreciation from groups involved in drug discovery of the value of greater openness and collaboration in the process. This has led to the establishment of pre-competitive collaborations and initiatives based on various levels of open access. Many groups have been experimenting with new ways of working, exploring models that utilise differing levels of engagement and transparency (3).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Benoît Laleu is leading the Pathogen Box project at Medicines for Malaria Venture (MMV), where he is a Research Scientist in the Drug Discovery department. Before joining MMV in 2015, he spent seven years as a Medicinal Chemist at GenKyoTex, a Swiss biotechnology company. Benoît holds a PhD in Chemistry from the University of Geneva, Switzerland, and completed postdoctoral studies at the University of Toronto, Canada. 

Jaya Banerji is Director of Communications and Advocacy at MMV and works with a team of communications and fundraising professionals to raise awareness about the need for continued R&D for malaria. She has over two decades of communications experience gained in India, the Middle East, Switzerland and the UK, from both public and private sector organisations. Jaya holds an MPH from the University of Liverpool, UK. 

Paul A Willis is Director of Drug Discovery at MMV, where he has responsibility for a portfolio of drug discovery projects working with major pharmaceutical companies and academic groups. He also coordinates many of MMV’s open science activities. Before joining MMV in 2011, Paul was employed by AstraZeneca, first as a Medicinal Chemist then as a Project Leader, working on cardiovascular, respiratory and anti-inflammatory drug discovery projects. He has a PhD in Organic Chemistry from the University of Southampton, UK, and carried out postdoctoral studies at the University of Texas at Austin, US. 
spacer
Benoît Laleu
spacer
spacer
spacer
Jaya Banerji
spacer
spacer
spacer
Paul A Willis
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Aptar Pharma Partners with Kali Care to Develop Real-Time Medication Management Technology

Aptar Pharma and Kali Care have announced that they entered into a partnership in order to address the challenge of monitoring adherence in ophthalmic clinical trials. The combination of Aptar Pharma’s ophthalmic device expertise, and Kali Care’s ground-breaking digital monitoring system for ophthalmic medications, is likely to have a significant impact in reducing the costs and complexity of ophthalmic clinical trials.
More info >>

White Papers

CRSF Label - Child-Resistant Blister Packs With Booklet Label

Faubel & Co. Nachfolger GmbH

This case study explains how Faubel was commissioned by a leading global pharmaceutical company to develop a label for an aluminum blister pack with 14 cavities, which was used as part of a multinational clinical trial. This label was intended to both protect infants from erroneous ingestion and facilitate use by seniors.
More info >>

 
Industry Events

PREP_2017

16-19 July 2017,

Advances in Separation Technologies: The PREP series of symposia is the most recognized international conference and exposition devoted to advances in separation technologies in the field of preparative and process chromatography. Join us at PREP 2017 for another dynamic and innovative program where experts from around the world will address the latest developments and hottest topics in all areas of preparative and process chromatography.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement